Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Ultrasonic Medical Mapping, Inc., (UMM) is headquartered in Bethesda, MD. The comp...
Ultrasonic Medical Mapping, Inc., (UMM) is head...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
BIONIK is a global pioneering healthcare company on a mission to supply quality-of...
BIONIK is a global pioneering healthcare compan...
LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...
LogicBio is a Cambridge, MA-based genome editin...
Pacific Biosciences' mission is to transform the way humankind acquires, processes...
Pacific Biosciences' mission is to transform th...
Novartis is reimagining medicine to improve and extend peoples lives. As a leadin...
Novartis is reimagining medicine to improve and...
Join the National Investor Network and get the latest information with your interests in mind.